4Cbiomed
1 known investors
4C Biomed develops immuno-oncology therapies using a patient-derived discovery platform that identifies novel immune targets from autologous cancer and immune cell systems. Its lead drug has completed IND-enabling studies and is planned to enter Phase I clinical trials in 2026.
BiotechHealthtech